- Home
- DSP vs ABOS Comparison
DSP vs ABOS Comparison
Compare DSP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ABOS
- Stock Information
- Founded
- DSP 1999
- ABOS 1996
- Country
- DSP United States
- ABOS United States
- Employees
- DSP N/A
- ABOS N/A
- Industry
- DSP EDP Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- ABOS Health Care
- Exchange
- DSP Nasdaq
- ABOS Nasdaq
- Market Cap
- DSP 139.8M
- ABOS 109.6M
- IPO Year
- DSP 2021
- ABOS 2021
- Fundamental
- Price
- DSP $9.83
- ABOS $1.57
- Analyst Decision
- DSP Strong Buy
- ABOS Strong Buy
- Analyst Count
- DSP 9
- ABOS 3
- Target Price
- DSP $19.44
- ABOS $7.67
- AVG Volume (30 Days)
- DSP 301.2K
- ABOS 210.6K
- Earning Date
- DSP 11-10-2025
- ABOS 11-12-2025
- Dividend Yield
- DSP N/A
- ABOS N/A
- EPS Growth
- DSP 29.49
- ABOS N/A
- EPS
- DSP 0.10
- ABOS N/A
- Revenue
- DSP $324,131,000.00
- ABOS N/A
- Revenue This Year
- DSP $16.39
- ABOS N/A
- Revenue Next Year
- DSP $14.89
- ABOS N/A
- P/E Ratio
- DSP $99.62
- ABOS N/A
- Revenue Growth
- DSP 22.97
- ABOS N/A
- 52 Week Low
- DSP $8.11
- ABOS $0.86
- 52 Week High
- DSP $26.33
- ABOS $2.47
- Technical
- Relative Strength Index (RSI)
- DSP 55.78
- ABOS 37.01
- Support Level
- DSP $9.32
- ABOS $1.51
- Resistance Level
- DSP $10.93
- ABOS $1.72
- Average True Range (ATR)
- DSP 0.58
- ABOS 0.16
- MACD
- DSP 0.02
- ABOS -0.06
- Stochastic Oscillator
- DSP 57.59
- ABOS 10.61
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.